Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitrafy Life SciencesASX:VFY -0.71%5 PB Ratio is 8.29 as of Jul. 21, 2026, which is 173% above its 10-year median of 3.04. GuruFocus rates ASX:VFY with a GF Score™ of 5/100. The stock has 5 warning signs investors should review. Among 2,636 Software companies, Vitrafy Life Sciences ranks worse than 88.2% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Software - Infrastructure subindustry, Vitrafy Life Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrafy Life Sciences PB Ratio vs Software Industry
For the Software industry and Technology sector, Vitrafy Life Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Vitrafy Life Sciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Vitrafy Life Sciences (ASX:VFY) has a PB Ratio of 8.29 as of Jul. 21, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vitrafy Life Sciences and its competitors. This is 173% above median its historical median of 3.04. Over the past decade, Vitrafy Life Sciences' PB Ratio has ranged from 1.74 to 8.35. According to the industry distribution chart, Vitrafy Life Sciences ranks #2325 out of 2636 companies in the Software industry, placing it in the top 88.2%.
Is Vitrafy Life Sciences' PB Ratio too high?
Vitrafy Life Sciences' current PB Ratio of 8.29 is 173% above median its 10-year median of 3.04. Over the past 10 years, this metric has ranged from a low of 1.74 to a high of 8.35. The Software industry median PB Ratio is 2.37. Vitrafy Life Sciences' value of 8.29 is 249.8% above this industry median. Based on the distribution chart, Vitrafy Life Sciences ranks #2325 out of 2636 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, Vitrafy Life Sciences has a GF Score™ of 5/100, reflecting its overall financial health beyond just this single metric.
How does Vitrafy Life Sciences' PB Ratio compare to MSFT and ORCL?
According to the Software industry distribution chart, Vitrafy Life Sciences ranks #2325 out of 2636 companies for PB Ratio. This places Vitrafy Life Sciences in the lower half of its industry. The industry median PB Ratio is 2.37. Vitrafy Life Sciences' value of 8.29 is 249.8% above this benchmark. Historically, Vitrafy Life Sciences' own PB Ratio has ranged from 1.74 to 8.35 over the past decade. While the company's 10-year median is 3.04 vs. the industry median of 2.37, Vitrafy Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Software company?
The median PB Ratio among Software companies is 2.37, based on 2,636 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitrafy Life Sciences's current PB Ratio of 8.29 is 249.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vitrafy Life Sciences and its competitors. For the Software industry, the median PB Ratio is 2.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitrafy Life Sciences's current PB Ratio is 8.29, which is 173% above median its own 10-year median of 3.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrafy Life Sciences stock overvalued right now?
Vitrafy Life Sciences (ASX:VFY) has a current PB Ratio of 8.29. The current PB Ratio is 8.29, which is 173% above median its 10-year median of 3.04 and 249.8% above the Software industry median of 2.37. Vitrafy Life Sciences' overall GF Score™ is 5/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Vitrafy Life Sciences (ASX:VFY), the current PB Ratio is 8.29 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitrafy Life Sciences Ltd developed a range of proprietary smart cryopreservation hardware devices and Lifechain, an integrated, cloud-based software platform, to provide a complete, vertically integrated cryopreservation solution to retain the quality of cryopreserved biomaterials. The company devices includes Vitrafy's Smart Cryopreservation Device; Vitrafy's Smart Thawing Device and Vitrafy's Smart Packaging.
5GF Score
Get the complete analysis for ASX:VFY
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VFY has been successfully added to your 
